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lesterol precursor lathosterol were higher in carriers of 
the  CH25H  4  haplotype. In 1,282 patients with AD and 
1,312 healthy control subjects from fi ve independent 
populations, a common variation in the vicinity of  CH25H 
was signifi cantly associated with the risk for sporadic AD 
(p = 0.006). Quantitative neuropathology of brains from 
elderly non-demented subjects showed brain A  depos-
its in carriers of  CH25H  4 and  CH25H  3 haplotypes, 
whereas no A  deposits were present in  CH25H  2 carri-
ers. Together, these results are compatible with a role of 
 CH25H  4 as a putative susceptibility factor for sporadic 
AD; they may explain part of the linkage of chromosome 
10 markers with sporadic AD, and they suggest the pos-
sibility that  CH25H polymorphisms are associated with 
different rates of brain A  deposition. 
 Copyright © 2005 S. Karger AG, Basel 
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 Abstract 
 Alzheimer’s disease (AD) is the most common cause of 
dementia. It is characterized by   -amyloid (A  ) plaques, 
neurofi brillary tangles and the degeneration of specifi -
cally vulnerable brain neurons. We observed high ex-
pression of the cholesterol 25-hydroxylase  (CH25H) gene 
in specifi cally vulnerable brain regions of AD patients. 
 CH25H maps to a region within 10q23 that has been pre-
viously linked to sporadic AD. Sequencing of the 5  re-
gion of  CH25H revealed three common haplotypes, 
 CH25H  2 ,  CH25H  3 and  CH25H  4 ; CSF levels of the cho-
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 Introduction 
 Alzheimer’s disease (AD) is the most common cause 
of dementia. It is characterized by   -amyloid (  A) plaques, 
neuroﬁ brillary tangles (NFTs) and the degeneration of 
speciﬁ cally vulnerable brain neurons. Degeneration of 
neurons in AD occurs predominantly in such brain re-
gions as the hippocampus, the inferior temporal cortex, 
the entorhinal cortex and the amygdala. The relative pro-
tection from degeneration of neuronal populations in the 
frontal and the occipital cortex  [1] indicates selective vul-
nerability of speciﬁ c neurons in brain regions involved in 
cognitive and memory processes. 
 We previously demonstrated speciﬁ c downregulation 
of seladin-1  (DHCR24) , encoding 24-dehydrocholesterol 
reductase (seladin-1), in the inferior temporal cortex in 
AD using a differential mRNA display approach  [2] ; 
downregulation of  DHCR24 is reportedly associated with 
pathologic phosphorylation of tau, the major protein-
aceous constituent of NFTs in AD  [3] . 
 In this study, we targeted a priori  CH25H , encoding 
cholesterol 25-hydroxylase. The intronless  CH25H codes 
for a polytopic membrane protein of 272 amino acids and 
plays an important role in lipid metabolism  [4] . By syn-
thesizing 25-hydroxycholesterol, a potent co-repressor of 
SREBP (sterol regulatory element binding protein) pro-
cessing,  CH25H is involved in the transcriptional regula-
tion of lipid-related genes. Importantly,  CH25H maps 
within a 30-cM-broad region on chromosome 10q, which 
has been recently linked to late-onset AD  [5–7] . In addi-
tion,  CH25H is known to be upregulated in the spinal 
cord of patients with amyotrophic lateral sclerosis  [8] , 
suggesting a potential role in neurodegeneration.  
 Because recent genetic evidence suggests that choles-
terol- and lipid-related genes are associated with the risk 
for AD  [9–14] , we examined the differential expression of 
 CH25H in AD, its potential association with disease risk, 
as well as its association with A  plaque deposition. 
 Subjects and Methods 
 Differential mRNA Expression Studies 
 Brain tissues from 12 aged individuals with Braak stages rang-
ing from 0 to 6 were dissected and immediately frozen in liquid 
nitrogen, on average within 5 h postmortem. Brain areas for dif-
ferential expression analysis were identiﬁ ed and stored at –80  °  C 
until RNA extractions were performed. In order to compare RNA 
populations from carefully selected postmortem brain tissues (hip-
pocampus, and frontal and inferior temporal cortex), qPCR using 
the LightCycler TM  was employed. The ratio of the normalized 
amount of candidate gene cDNA from the temporal cortex or hip-
pocampus and frontal cortex was determined (relative quantiﬁ ca-
tion). The following strategy was used for normalization: Xenopus 
  -globin mRNA spiked into the mRNA of each brain tissue was 
used as a qPCR standard to normalize differences in the cDNA 
synthesis efﬁ ciency. Additionally, the qPCR procedure was applied 
to a set of housekeeping genes, which were selected as a reference 
standard for quantiﬁ cation. The ratio of the amount of frontal and 
temporal mRNA of ﬁ ve such housekeeping genes (cyclophilin B, 
ribosomal protein S9,   -actin, GAPDH and transferrin receptor) 
was determined, the mean value from the ﬁ ve ratios calculated and 
used for normalization of candidate gene expression. Primers for 
qPCR of  CH25H were 5  -GGT CAA CAT CTG GCT TTC CG-3  
(forward) and 5  -CAC CAG TCT GTG AGT GGA CCA A-3  (re-
verse). 
 Genetic Association Studies 
 Genetic studies were conducted on ﬁ ve independent popula-
tions: a Swiss sample (174 AD patients and 285 controls), a Medi-
terranean sample from Greece and Italy (272 AD patients and 125 
controls), a Russian sample (74 AD patients and 90 controls), a 
French sample (551 AD patients and 665 controls) and a US sam-
ple derived from the NIMH Human Genetics Initiative and from 
the National Cell Repository for Alzheimer’s Disease (NCRAD; 
grant No. U24 AG21886; 211 AD patients and 147 controls). The 
diagnosis of AD was performed according to the NINCDS-ADRDA 
criteria. The control groups comprised cognitively healthy elderly 
individuals who were either the spouses of AD patients or subjects 
recruited from the outpatient clinics of the participating institu-
tions. 
 Neuropathological Studies 
 Neuropathological examinations were performed in the brains 
of 71 elderly individuals (mean age of death: 71.6 years, range 50–
91 years, 28 females) devoid of signiﬁ cant neuropathological ab-
normalities and without signs of dementia, as measured by the 
Clinical Dementia Rating scale  [15] . The evolutionary phases 
(0–4) of   -amyloidosis in the medial temporal lobe of these subjects 
were determined as described previously  [16, 17] . NFT staging 
(0–6) was performed according to Braak and Braak  [18] . For geno-
type determination, DNA was extracted from fresh-frozen samples 
of cerebelli following standard protocols. 
 CSF Studies 
 CSF was obtained by lumbar puncture in a subset of the par-
ticipants of the genetic studies in Zurich. Forty-ﬁ ve AD patients 
(mean age: 70.1 years) and 27 healthy elderly subjects (mean age: 
65.4 years) were included. For CSF A   42  analysis, we used a sand-
wich ELISA (INNOTEST   -Amyloid 1–42, Innogenetics) with 
mAb 21F12 – speciﬁ c for the free C-terminal end of A   42  (peptide 
sequence A  33–42) – as capturing antibody and mAb 3D6 – spe-
ciﬁ c for the N-terminal end of A   42  (peptide sequence A  1–5) – as 
detector. CSF lathosterol was measured by means of combined gas 
chromatography/mass spectrometry  [19] . 
 SNP Selection and Genotyping 
 Information on polymorphic sites of 10q23–24 was derived 
from the database of single nucleotide polymorphisms (dbSNP) 
established by the National Center for Biotechnology Information 
(http://www.ncbi.nlm.nih.gov/SNP/index.html), and from the 
Celera database (www.celera.com). The following genes were se-
D
ow
nl
oa
de
d 
by
: 
Un
ive
rs
itä
ts
bi
bl
io
th
ek
 M
ed
izi
n 
Ba
se
l  
   
   
   
   
   
  
13
1.
15
2.
21
1.
61
 - 
10
/1
1/
20
17
 3
:1
5:
28
 P
M
 CH25H on 10q in Alzheimer’s Disease  Neurodegenerative Dis 2005;2:233–241 235
lected due to possible relevance for AD:  PTEN (phosphatase and 
tensin homolog),  ACTA2 (   2 -actin),  TNFRSF6 (tumor necrosis fac-
tor receptor superfamily, member 6),  CH25H (cholesterol 25-hy-
droxylase),  LIPA  (lipase A),  PPP1R3C (protein phosphatase 1, reg-
ulatory subunit 3C),  CYP2C8 [cytochrome P 450 , subfamily IIC 
(mephenytoin 4-hydroxylase), polypeptide 8],  TLL2 (tolloid-like 
2),  SLIT1 (slit homolog 1),  PGAM1 (phosphoglycerate mutase 1), 
 SFRP5 (secreted frizzled-related protein 5),  HPA2 (heparanase 2), 
 GOT1 (glutamic-oxaloacetic transaminase 1),  COX15 (COX15 ho-
molog),  WNT8B (wingless-type MMTV integration site family), 
 NEURL (neuralized-like),  SLK (Ste20-related serine/threonine ki-
nase), and  GSTTLp28 (glutathione-S-transferase like). In these 
genes, the following SNPs were analyzed: rs1903858, rs1389, 
rs1324551, hCV399212, rs13500, rs1131706, rs1556478, 
rs1051339, rs1051338, rs1044563, rs2068888, rs1058932, 
rs730179, rs902471, rs716838, rs1126878, rs2075430, rs1556971, 
rs2236278, rs2970, rs1047425, rs805657, and rs4925. SNP identi-
ﬁ cation in the ORF, the 5  and the 3  region of  CH25H , was done 
by double-stranded sequencing of 40 chromosomes on an ABI 
PRISM ®  310 Genetic Analyzer. The Masscode TM  system was used 
for SNP genotyping  [20] . 
 Statistics 
 Genotype and allelic frequencies between AD patients and con-
trols were compared by Fisher’s exact tests. Forward and backward 
unconditional logistic regression analyses were done for the simul-
taneous assessment of the inﬂ uence of age, gender,  APOE and 
 CH25H genotypes on the risk for developing AD. The estimate 
haplotype frequencies program was used to test for linkage disequi-
librium (LD) between SNPs and for signiﬁ cance of haplotype dis-
tribution between AD cases and controls  [21] . The FBAT and SDT 
algorithms were used for family-based association analysis  [22] . 
Phases of   -amyloidosis between groups were compared with the 
U test by Wilcoxon, and Mann and Whitney. The signiﬁ cance of 
correlation between  CH25H mRNA expression levels and NFT stag-
es was assessed by Spearman’s rank correlation coefﬁ cient. For the 
comparison of CSF A   42  and lathosterol levels, t tests were used. 
 Results 
 First-Stage Analysis 
 Using comprehensive differential display  [23, 24] and 
real-time quantitative PCR analyses, we observed high 
 CH25H (encoding cholesterol 25-hydroxylase) expression 
in such vulnerable brain regions as the inferior  temporal 
cortex and the hippocampus in AD patients ( ﬁ g. 1 ). 
 We then sequenced the ORF and 6.8 kb of the 5  ge-
nomic region of  CH25H  and identiﬁ ed two synonymous 
SNPs, four 3  SNPs, and six 5  SNPs. Haplotype analysis 
revealed three common haplotypes, designated CH25H  2 , 
 CH25H  3 and  CH25H  4 , composed of SNP  CH25H*1 
at  –6443 bp and SNP  CH25H*2 at  –6627 bp ( ﬁ g. 2 ). 
0 1 2 4 5 6
Braak NFT stage 
100%
80%
60%
40%
20%
0%
20%
40%
60%
80%
100%
C
H
25
H
 m
R
N
A
 (
%
 c
h
an
g
e)
fr
o
n
ta
l l
o
b
e
in
fe
ri
o
r
te
m
p
o
ra
l l
o
b
e
 Fig. 1.  CH25H  mRNA overexpression in 
vulnerable brain regions in late Braak stag-
es. Expression analysis of  CH25H mRNA 
was done in the inferior temporal lobe and 
the frontal lobe from brains of 12 aged in-
dividuals with Braak stages ranging from 0 
to 6. A value of 0% indicates equal  CH25H 
mRNA expression levels in the inferior 
temporal lobe and the frontal lobe. Bars rep-
resent means of expression ratios  8 SEM. 
Normalization for housekeeping genes. p = 
0.016 (Spearman’s rank correlation). Com-
parison of  CH25H mRNA levels between 
the hippocampus and the frontal lobe from 
brains of 9 aged individuals showed signiﬁ -
cant mRNA elevation up to Braak stage 5 
(Rs = 0.8, p = 0.031; data not shown). 
..AGTGTCCTAGTTCATTTTCAC...TTACAATACTGTCTGGTGGA.. CH25H χ1  0%
..AGTGTCCTAGTTCATTTTCAC...TTACAATACTGTCCGGTGGA.. CH25H χ2  24%
..AGTGTCCTTGTTCATTTTCAC...TTACAATACTGTCCGGTGGA.. CH25H χ3  66%
..AGTGTCCTTGTTCATTTTCAC...TTACAATACTGTCTGGTGGA.. CH25H χ4  10%
184 bp 
CH25H*1CH25H*2
Haplotype Frequency
 Fig. 2. LD between SNP  CH25H*1 at
–6443 bp and SNP  CH25H*2 at –6627 bp 
(relative to the start codon of  CH25H ). 
Haplotypes were reconstructed by includ-
ing individuals homozygous for one or both 
SNPs. Subjects heterozygous for both SNPs 
were excluded. 
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 Fig. 3. SNPs in the 5  UTR of CH25H were signiﬁ cantly associated with AD.  a Allelic association of SNPs on 
10q with AD. Values on the y-axis represent the negative logarithm of the signiﬁ cance p (   2  test for allelic asso-
ciation). The horizontal continuous line represents the signiﬁ cance level of 0.05, the dotted line represents the 
signiﬁ cance level after Bonferroni correction for all SNPs analyzed. Distance from p-ter is given in the x-axis in 
cM according to the NCBI map.  b Fine mapping of the  CH25H locus at 90 cM.  CH25H*1 : [T-6443C], corresponds 
to SNP rs13500;  CH25H*2 : [A-6627T], corresponds to SNP rs1131706; CH25H*3 : [C-1710T]; CH25H*4 : [A-
054G]; CH25H*5 : [A-44G]; CH25H*6 : [T503C]; CH25H*7 : [A656G];  LIPA*1 : corresponds to SNP rs1556478. 
SNP positions were calculated in relation to the start codon of  CH25H . 
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 Genetic data in Caucasian populations ( www.celera.
com ) indicate that both  CH25H*1 and  CH25H*2 are lo-
cated within an extended haplotype covering  CH25H and 
 LIPA (encoding lipase A, also known as cholesterol ester 
hydrolase).  LIPA was not found to be differentially ex-
pressed in our analysis. Because the reported linkage peak 
on 10q may result from the combined effect of multiple 
susceptibility genes, we assessed the association between 
AD and 18 possibly relevant genes within a 20-cM-broad 
region on 10q23–24. Both SNPs and extended haplotypes 
were analyzed in 446 AD patients and 410 unrelated con-
trol subjects from Switzerland and the Mediterranean re-
gion (Greece and Italy). SNP  CH25H*1 showed signiﬁ -
cant allelic association with AD (p =  0.0002,  ﬁ g. 3 a). Fine 
mapping of an 18-kb region around  CH25H*1 and sub-
sequent estimated haplotype analysis revealed strong LD 
between SNPs  CH25H*1 and CH25H*2 in the Swiss pop-
ulation (p  ! 0.001) and weak LD in the Mediterranean 
population (p = 0.02). Association mapping of two syn-
onymous SNPs in  CH25H , ﬁ ve SNPs in the 5  region of 
the gene and three SNPs in the adjacent  LIPA gene in the 
Swiss population revealed signiﬁ cant allelic association 
of  CH25H*1 ,  CH25H*2 , and  CH25H*7 with AD ( ﬁ g. 
3 b). Haplotype  CH25H  reached the highest signiﬁ cance 
of association with AD. Signiﬁ cant allelic and haplotypic 
association of  CH25H*1  and  CH25H  with AD was also 
observed in the combined sample (p = 0.0002, p = 0.00003, 
respectively;  table 1 ). In the Mediterranean sample, sig-
niﬁ cant association was observed for  CH25H*1 and 
 CH25H  (p  ! 0.05), but not for  CH25H*2 (p  1 0.1). An 
additive interaction between  APOE4 and  CH25H  4 was 
observed in the combined sample. Compared with indi-
viduals lacking the  APOE4 allele and the  CH25H  4 hap-
lotype, the odds ratio for carriers of both  APOE4 and 
 CH25H  4 was 5.5 (95% conﬁ dence interval: 2.8–10.9). 
The odds ratios and 95% conﬁ dence intervals were 3.1 
(2.1–4.5) for  APOE4 carriers and 2.7 (1.5–4.8) for 
 CH25H  4 carriers. In addition to  CH25H  , two addi-
tional haplotypes containing  CH25H*1 showed signiﬁ -
cant, yet less pronounced association with AD ( ﬁ g. 3 b). 
Seventeen SNPs within the examined region on 10q failed 
to show signiﬁ cant allelic association with AD in the 
study populations. 
 SNP  CH25H*2 is located within the core sequence 
(CTTG) of the functional binding site for the steroido-
genic factor 1 (SF-1)  [25, 26] , which is involved in the 
transcriptional regulation of steroid hydroxylases  [27] 
Table 1. Signiﬁ cantly different distribution of the CH25H4 hap-
lotype and the CH25H*1 T allele between AD patients and healthy 
control subjects (HCS) in the combined sample of the ﬁ rst-stage 
analysis
HCS, %
(n = 410)
AD, % 
(n = 446)
p value
CH25H 4 haplotype 11.4 22.2 0.00003
CH25H*1 T allele 13.9 23.8 0.0002
CH25H*2 A allele 23.9 20.8 0.28
✽
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 Fig. 4.  a Higher CSF concentrations of lathosterol in diseased carriers of the  CH25H  4 haplotype as compared to 
diseased non-carriers (* p = 0.05, Student’s t test).  b Low CSF concentrations of soluble A   42  in  CH25H  4 carri-
ers, intermediate concentrations in  CH25H  3 carriers, and high concentrations in  CH25H  2 carriers (* p = 0.002, 
ANOVA).  c Signiﬁ cantly lower CSF concentrations of soluble A   42  in diseased  CH25H  4 carriers as compared to 
diseased  CH25H  3 carriers (* p = 0.014, Student’s t test). The difference between healthy  CH25H  3 and  CH25H  2 
carriers was not signiﬁ cant. Bars represent means  8 SEM. AD = AD patients; HCS = healthy control subjects. 
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and lipoprotein receptors  [28] . Because allele  A of 
 CH25H*2 eliminates the SF-1 binding site, which results 
in impaired activity of SF-1-dependent regulatory regions 
 [25] , and because  CH25H is a potent regulator of choles-
terol synthesis  [4] , we examined whether the  CH25H*2 -
containing haplotype  CH25H  is associated with the lev-
els of metabolic precursors of cholesterol. We found that 
the concentration of the cholesterol precursor lathosterol 
in CSF of  CH25H  4 carriers was signiﬁ cantly higher than 
in non-carriers ( ﬁ g. 4 a). 
 To investigate whether  CH25H  exerts effects rele-
vant to the pathophysiology of AD, we examined wheth-
er  CH25H haplotypes differentially affected A  plaque 
pathology. Brain samples from the medial temporal lobes 
of AD patients are ill suited for the study of genetic effects 
on amyloid load because they invariantly show highest 
levels of A  plaque pathology. Therefore, we prevented 
such ceiling effects and examined the brains of 71 elderly 
non-demented subjects (age at death  6 50 years). We ob-
served that both  CH25H  4 and  CH25H  3 were associ-
ated with high scores of brain A  deposition, whereas no 
A  deposits were present in  CH25H  2 carriers (p = 0.002, 
 table 2 ). In contrast, Braak’s NFT staging  [18] was similar 
among haplotype groups (p = 0.7). The  CH25H  - related 
differences in brain A  deposition were paralleled by low 
CSF levels of A   42  in  CH25H  4 carriers, intermediate 
levels in  CH25H  3 carriers, and high levels in  CH25H  2 
carriers ( ﬁ g. 4 b, c). 
 Second-Stage Analysis 
 The signiﬁ cant association of SNP  CH25H*1 with the 
risk for AD prompted us to validate this ﬁ nding in ethni-
cally independent case-control series from Russia (n = 
164) and France (n = 1,216). We also genotyped a large 
sample of siblings who were part of the NIMH Human 
Genetics Initiative and the NCRAD (grant No. U24 
AG21886) and applied family-based and case-control an-
alytical methods. 
 Consistent with the ﬁ ndings in the Swiss and Mediter-
ranean populations, the  T allele of  CH25H*1 was signiﬁ -
cantly overrepresented in Russian AD patients as com-
pared to control subjects (p = 0.031,  table 3 ). This was 
not the case in the French sample (p = 0.3). Family-based 
analysis (using both the FBAT and the SDT algorithms) 
Table 3. Genetic ﬁ ndings of SNP CH25H*1 in ethnically indepen-
dent populations
CH25H*1 genotypes Control subjects AD patients
Swiss sample
      Total 285 174
C/C 246 (86.3%) 133 (76.4%)
C/T or T/T  39 (13.7%) 41 (23.6%)
      Statistics 2 = 7.3, d.f. = 1, p = 0.007
Mediterranean sample
      Total 125 272
C/C 107 (85.6%) 207 (76.1%)
C/T or T/T 18 (14.4%) 65 (23.9%)
      Statistics 2 = 4.7, d.f. = 1, p = 0.031
Russian sample
      Total 90 74
C/C 78 (86.7%) 55 (74.3%)
C/T or T/T 12 (13.3%) 19 (25.7%)
      Statistics 2 = 4.0, d.f. = 1, p = 0.045
French sample
      Total 665 551
C/C 530 (79.7%) 452 (82.0%)
C/T or T/T 135 (20.3%)  99 (18.0%)
      Statistics 2 = 1.1, d.f. = 1, p = 0.304
NIMH/NIA sample
      Total 147 211
C/C 129 (87.8%) 164 (77.7%)
C/T or T/T 18 (12.2%) 47 (22.3%)
      Statistics 2 = 5.9, d.f. = 1, p = 0.015
Combined sample
      Total 1,312 1,282
C/C 1,090 (83.1%) 1,011 (78.9%)
C/T or T/T 222 (16.9%) 271 (21.1%)
      Statistics 2 = 7.5, d.f. = 1, p = 0.006
Table 2. Brain A load in the medial temporal lobe differs between 
CH25H haplotypes and alleles
n A load p value
CH25H haplotype
4
3
2
10
44
17
1.580.9
1.080.6
0.080.0
<0.002
CH25H*1 T allele
T+
T– 
10
61
1.580.9
0.080.3
<0.127
CH25H*2 A allele
A+
A–
19
52
0.080.0
1.080.6
<0.001
Brain A load: values represent blindly scored phases of 4A 
load and are given as medians 8 SEM. Statistical comparisons: H 
test (CH25H haplotypes) and U test (CH25H*1 and CH25H*2 
alleles).
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in the NIMH sample also failed to yield signiﬁ cant results 
(p  1 0.1). Discrepancies between family-based and case-
control approaches are common and may be related to 
the differential proportions of positive family history be-
tween samples  [29] . Therefore, we selected from the sib-
pair sample a group of AD patients and unrelated control 
subjects to compare the family-based and case-control 
results in the same population. We selected the controls 
(n = 147) from sibships with at least one control subject. 
Where two or more control subjects were present, the old-
est one was chosen. Unrelated AD patients (n = 211) were 
selected from the remaining sibships. Where possible, au-
topsy-veriﬁ ed cases and controls were selected. Associa-
tion analysis in that sample conﬁ rmed the signiﬁ cant re-
sults obtained in the Swiss, Mediterranean and Russian 
populations: the  T allele of  CH25H*1 was signiﬁ cantly 
overrepresented in the US AD patients as compared to 
the control subjects (p = 0.015,  table 3 ). Importantly, the 
genotype frequencies were nearly identical across popula-
tions. In addition, a compound analysis in the pooled 
case-control sample (1,282 AD patients and 1,312 control 
subjects) revealed a signiﬁ cant effect of the  CH25H*1 
SNP on AD risk (p = 0.006). 
 Discussion 
 Since the ﬁ rst report of genetic linkage of sporadic AD 
to chromosome 10q  [6] , subsequent studies narrowed 
down the genetic region of interest  [5, 30, 31] . By combin-
ing the information of genome scans with a novel candi-
date gene approach that is based upon speciﬁ c informa-
tion on gene expression levels in the brain, we found evi-
dence that  CH25H is expressed differentially in brains of 
patients with AD, and that genetic variants in the vicin-
ity of this gene are associated with the risk for sporadic 
AD. We obtained signiﬁ cant associations in four ethni-
cally independent populations, whereas no signiﬁ cant as-
sociation was observed in a sample of French patients and 
control subjects. Analysis in the pooled sample of 1,282 
AD patients and 1,312 control subjects conﬁ rmed the sig-
niﬁ cant association of  CH25H*1 with AD. It is therefore 
unlikely that the ﬁ ndings reported here are due to random 
effects or multiple testing. They rather underscore the 
importance of ethnicity as an important confounding fac-
tor in genetic association analyses. 
 In addition to the genetic ﬁ ndings in the case-control 
populations, we found evidence that  CH25H is related to 
the pathophysiology of AD, because the risk haplotype 
 CH25H  4 was associated with high brain A  load and 
low levels of soluble A   42  in the CSF. The association of 
 CH25H  4 with high A  load in the medial temporal lobe 
suggests that this genetic variant enhances pathologic am-
yloidogenesis in vulnerable areas of the human brain. At 
the same time,  CH25H  4 was found to be related to  low 
levels of soluble A   42  in the CSF. A  is secreted as a sol-
uble protein to the extracellular space, including CSF, as 
part of the normal constitutive metabolism of amyloid 
precursor protein  [32] . Since the CSF is in direct contact 
with the extracellular space of the brain, biochemical 
changes in the brain may be reﬂ ected in the CSF. How-
ever, the relationship between brain and CSF A  is only 
poorly understood. Nevertheless, a decrease in CSF A   42  
in AD might reﬂ ect the deposition of the protein in senile 
plaques with low levels of soluble peptide remaining to 
diffuse to the CSF  [33] . Indeed, low levels of CSF A   42  
are robustly observed in AD, even in the very early stag-
es  [34] . Alternatively, the reduction in A   42  levels in the 
CSF of patients with AD may be secondary to a distur-
bance in the metabolism of amyloid precursor protein 
and A  in already dysfunctional neurons. Either way, our 
results show an aggravation of this AD-related phenotype 
(i.e. low A   42  levels in the CSF) in carriers of the  CH25H  4 
haplotype and, thereby, are in favor of the hypothesized 
relationship between  CH25H and amyloid metabolism. 
In addition, carriers of  CH25H  4 had increased CSF lev-
els of the cholesterol precursor lathosterol, supporting 
possible physiological differences of the haplotypes in the 
transcriptional regulation of  CH25H .  
 We conclude that  CH25H is genetically associated 
with the risk for sporadic AD, with the severity of A  de-
position in the brain and with the levels of soluble A   42  
in the CSF. By modulating the ﬂ uidity and structural in-
tegrity of the cell membrane, cholesterol inﬂ uences the 
membrane-bound proteolytic processing of amyloid pre-
cursor protein. We therefore hypothesize that the asso-
ciation of  CH25H with AD is linked to the effects of 
 CH25H on cellular cholesterol biosynthesis. In support 
of this hypothesis, the examined  CH25H haplotype in the 
5  ﬂ anking region of the gene was related to the CSF lev-
els of metabolic precursors of cholesterol.  
 CH25H is located within an AD-linked chromosomal 
region on 10q. The available genetic data suggest the ex-
istence of more than one susceptibility gene in this region, 
possibly proximal to  CH25H . Further studies are needed 
for the identiﬁ cation of these genes, which in sum may 
contribute to a genetic risk proﬁ le for sporadic late-onset 
AD. 
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